Skip to main content
. 2022 Mar 9;113(4):1377–1392. doi: 10.1111/cas.15245

FIGURE 3.

FIGURE 3

Overall survival in patients with higher‐risk MDS after AZA failure. AZA, Azacitidine; MDS, myelodysplastic syndromes; OS, overall survival